About company:-
Emcure Pharmaceuticals, Headquartered at Pune, is a Indian pharmaceutical company in western India. The company's products include tablets, capsules (softgel capsules and hard-gel capsules) and injectionbell.
Indian plants:-
1) Solid Dosage Facility at Hinjawadi - In 2006, Incorporated the US FDA to facilitate its solid dosages at Hinjewadi in Pune. In the internationally regulated market, there are many solid formulas for the factory.
2) Hinjewadi - Small Fine Parents Facilitated at US FDA, UK MHRA There is lefilication and PFS capability
3) Oncology Injectable Facility at Hinjewadi
4) Solid Oral facility at Jammu and Bhosari
5) Kurumbu- Approved API feature at USFDA
6) Biotech facility at Hinjwadi
7) R & D center in Ahmedabad and upcoming projects
US plants:-
USA - The company has a manufacturing facility and R & D center in East Brunswick, New Jersey, USA, USA.
Capital market:-
Emcure is now considering funding for an initial public offering for a while. In 2014, Blackstone sold its stake in the Bin Capital in Emcure.
Recalls:-
In 2010, there was a need to repay the three bancasses in the US market's bacterial product, due to the presence of Bacillus anthracis, Penicillium chrysogenum and E. Koli in some samples. In 2011, Teva recalled the batch of two products due to white tablets showing the presence of Yerchania pestis.
AIDS Initiative:-
Emcure has expressed concern through the initiative "Fight with AIDS" on HIV / AIDS and provides antiretroviral medicines in Africa, Asia Pacific and CIS. As a part of corporate social responsibility, they support pharmacy 'rhythm' of HIV / AIDS patients run by HIV / AIDS patients.
As part of the Global Access Program in Escrow, Astzenvier and Gilead Sciences have license agreements with Bristol-Myers Squibb for Tenofover.
Join WhatsApp
Join Telegram
